- Initial data from Phase 1 trial of IGM-2323 in relapsed/refractory non-Hodgkin’s lymphoma expected in the second half of 2020 - - IND filing for IGM-8444 planned in 2020 - - Company to host conference call today at 4:30 p.m. ET - MOUNTAIN VIEW, Calif.

MOUNTAIN VIEW, Calif. , March 19, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that it will report its fourth quarter and year-end 2019 financial results on

MOUNTAIN VIEW, Calif. , March 04, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that members of the management team will present at two upcoming investor

MOUNTAIN VIEW, Calif. , Feb. 06, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a global leader in the research and development of engineered therapeutic IgM antibodies, today announced that Fred Schwarzer , Chief Executive Officer, will present at two upcoming investor conferences:

- Expert in the research and development of apoptotic pathways and antibody drug conjugates - MOUNTAIN VIEW, Calif. , Jan. 07, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a global leader in the research and development of engineered therapeutic IgM antibodies, today announced the